Immunic (IMUX) Change in Accured Expenses (2013 - 2026)

Immunic has reported Change in Accured Expenses for 14 years, with the latest figure at $273000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 94.21% year-over-year to $273000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (down 177.5% YoY) and the FY2025 annual result came in at -$209000.0, up 95.7% from the prior year.
• Change in Accured Expenses improved to $273000.0 in Q1 2026 per IMUX's latest filing, from $16000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.7 million in Q1 2025 and troughed at -$6.1 million in Q1 2024.
• A 5-year average of -$283764.7 and a median of $12000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 645.92% in 2023, then slumped 24766.67% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$589000.0 in 2022, then surged by 102.04% to $12000.0 in 2023, then plunged by 24766.67% to -$3.0 million in 2024, then jumped by 100.54% to $16000.0 in 2025, then surged by 1606.25% to $273000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $273000.0, $16000.0, and $6000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.